SFRP1 and central nervous system cancer: U87 and U251 glioma cells upon pcDNA3.1‐SFRP1 treatment was found to have elevated SFRP1 and E‐cadherin expression and reduced p‐GSK‐3β, β‐catenin, N‐cadherin, Vimentin, and Snail expression, with no change in GSK‐3β expression (Figure 6A,B).